CDK1 and acute myeloid leukemia: Here, we targeted CDK1 with selective CDK1 inhibitor CGP and pan-CDK inhibitor FLA to recover EZH2 function, which significantly arrested cells in G2/M phase, and promoted apoptosis of DNMT3A-mutated AML cells.